Hemorrhoid Treatment Market Size, Share, Growth, and Industry Analysis, By Type (Suppository, Sprays, Creams & Ointments, Others), By Application (Hospital Pharmacy, Drug Stores & Retail Pharmacy, Online Pharmacy), Regional Insights and Forecast to 2035

•   
•   
  

  Download Free Sample to learn more about this report

    

HEMORRHOID TREATMENT MARKET OVERVIEW

The global Hemorrhoid Treatment Market size estimated at USD 1.13 billion in 2026 and is projected to reach USD 2 billion by 2035, growing at a CAGR of 6.51% from 2026 to 2035.

The Hemorrhoid Treatment Market is expanding steadily due to the increasing prevalence of anorectal disorders, aging populations, sedentary lifestyles, and dietary changes. More than 50% of adults experience hemorrhoid symptoms by the age of 50, creating sustained demand for pharmaceutical and minimally invasive treatment options. Over 78% of diagnosed patients initially receive conservative medication before surgical intervention, while nearly 22% require procedural treatment because of advanced disease severity. Prescription creams, ointments, suppositories, and office-based procedures account for a significant portion of clinical management. Improved diagnosis, greater awareness campaigns, and the availability of non-invasive therapies continue to strengthen the Hemorrhoid Treatment Market across hospitals, specialty clinics, and retail pharmacies.

The United States represents one of the largest contributors to the Hemorrhoid Treatment Market due to its high incidence of digestive disorders and obesity. Approximately 10 million Americans experience hemorrhoids annually, while nearly 75% of adults are expected to develop hemorrhoids during their lifetime. More than 63% of diagnosed patients prefer non-surgical therapies, and approximately 28% undergo minimally invasive procedures such as rubber band ligation or infrared coagulation. Hospital outpatient centers perform over 1 million anorectal procedures annually, supporting continuous demand for advanced treatment products, prescription medications, and specialized surgical devices throughout the country.

KEY FINDINGS

LATEST TRENDS

The Hemorrhoid Treatment Market is witnessing significant transformation because healthcare providers increasingly recommend minimally invasive treatment options and advanced pharmaceutical formulations. Clinical evidence indicates that almost 82% of Grade I and Grade II hemorrhoid patients respond effectively to conservative therapies, reducing the need for surgery. Topical creams, corticosteroid formulations, suppositories, and anesthetic preparations continue to dominate prescriptions due to their rapid symptom relief. Digital healthcare consultations have also increased patient accessibility, with online medical consultations for anorectal disorders rising by approximately 36% over the past few years. Furthermore, herbal and plant-derived formulations now account for nearly 18% of newly introduced hemorrhoid care products, reflecting consumer preference for natural ingredients.

Technological innovation has also improved procedural treatment. Rubber band ligation remains the preferred office-based intervention, accounting for nearly 46% of minimally invasive procedures worldwide. Infrared coagulation contributes approximately 19%, while sclerotherapy represents nearly 17% of procedural interventions. Disposable surgical instruments have witnessed greater adoption because hospitals prioritize infection prevention and operational efficiency. More than 71% of colorectal surgeons now utilize advanced disposable procedural kits. Patient awareness campaigns have increased screening participation by approximately 23%, supporting earlier diagnosis and improved treatment outcomes.

MARKET DYNAMICS

Driver

Rising prevalence of sedentary lifestyles and digestive disorders.

The growing incidence of obesity, chronic constipation, pregnancy-related hemorrhoids, and sedentary work environments remains the strongest growth driver for the Hemorrhoid Treatment Market. More than 58% of adults spend over 8 hours daily sitting, increasing the likelihood of anorectal disorders. Clinical studies indicate that approximately 65% of hemorrhoid patients have a history of chronic constipation, while obesity contributes to nearly 37% of diagnosed cases. Aging populations further strengthen market demand because nearly 54% of patients receiving hemorrhoid treatment are older than 45 years.

Restraint

Patient reluctance toward clinical consultation.

Despite increasing disease prevalence, delayed diagnosis remains a major challenge. Nearly 44% of individuals experiencing hemorrhoid symptoms postpone seeking professional care due to embarrassment. Approximately 39% depend exclusively on self-medication without physician supervision, while almost 27% discontinue prescribed therapy once symptoms temporarily improve. Rural healthcare accessibility also limits treatment availability, with specialized colorectal services available to only 36% of patients living outside major urban centers.

Expansion of minimally invasive treatment technologies

Opportunity

Demand for outpatient hemorrhoid management continues to increase because patients seek procedures requiring shorter recovery periods. Nearly 62% of physicians now recommend office-based interventions before considering surgery. Rubber band ligation demonstrates clinical success rates exceeding 85%, while infrared coagulation achieves symptom improvement in approximately 79% of treated patients.

Hospitals continue investing in disposable surgical instruments, advanced anoscopes, and energy-based treatment technologies to improve procedural efficiency.

Recurrence of hemorrhoid disease after treatment

Challenge

One of the most persistent clinical challenges involves disease recurrence following conservative treatment. Approximately 32% of patients experience symptom recurrence within several years if dietary and lifestyle modifications are not maintained. Nearly 48% of recurrent cases require repeated pharmaceutical therapy, while 19% eventually undergo procedural intervention.

Physician adherence to standardized treatment protocols varies across healthcare systems, creating differences in patient outcomes. Limited patient compliance with fiber-rich diets affects nearly 53% of diagnosed individuals, increasing recurrence risk.

•   
•   
  

  Download Free Sample to learn more about this report

    

HEMORRHOID TREATMENT MARKET SEGMENTATION

By Type

• Suppository: Suppositories remain an important segment of the Hemorrhoid Treatment Market because they deliver medication directly to the affected anorectal tissues and provide effective relief for internal hemorrhoids. This segment accounts for approximately 24% of the global market share by product type. Clinical observations indicate that nearly 69% of patients with Grade I and Grade II internal hemorrhoids experience symptom improvement within 7 days when suppositories are used according to prescribed treatment schedules. More than 61% of gastroenterologists recommend suppositories for patients presenting with rectal bleeding, inflammation, and discomfort associated with internal hemorrhoids.

• Sprays: Sprays represent a growing category in the Hemorrhoid Treatment Market because they provide hygienic application and minimize physical contact with inflamed tissue. This segment contributes approximately 11% of the total market share. Nearly 54% of patients choosing spray formulations cite ease of application as the primary reason for product selection. Cooling sprays containing local anesthetics and anti-inflammatory ingredients demonstrate symptom relief within 15 minutes for nearly 73% of users. Healthcare professionals increasingly recommend spray formulations following minimally invasive hemorrhoid procedures, with approximately 37% of post-procedure patients receiving spray-based therapies for pain management.

• Creams & Ointments: Creams and ointments dominate the Hemorrhoid Treatment Market with approximately 49% market share, making them the largest product segment. Their widespread adoption is supported by rapid symptom relief, affordability, and broad availability through hospital pharmacies, retail pharmacies, and online platforms. More than 76% of newly diagnosed hemorrhoid patients receive topical creams or ointments as first-line therapy. Products containing corticosteroids, lidocaine, zinc oxide, or herbal extracts account for nearly 68% of total topical prescriptions.

• Others: The "Others" category includes medicated wipes, gels, foams, herbal preparations, oral medications, and advanced procedural products. This segment represents approximately 16% of the Hemorrhoid Treatment Market. Medicated wipes account for nearly 34% of this category due to increasing emphasis on hygiene during hemorrhoid management. Oral flavonoid-based therapies contribute approximately 27%, while foam-based products represent nearly 18% because of improved patient comfort during application. Herbal preparations continue gaining popularity, particularly in Asia-Pacific, where they account for approximately 29% of non-prescription hemorrhoid treatment products.

By Application

• Hospital Pharmacy: Hospital pharmacies hold the leading position in the Hemorrhoid Treatment Market, accounting for approximately 41% of global distribution. Their dominance is supported by physician-directed prescribing practices and increasing outpatient treatment volumes. More than 74% of patients undergoing minimally invasive hemorrhoid procedures receive medications directly through hospital pharmacies. Prescription creams, corticosteroid suppositories, local anesthetics, antibiotics, and post-operative care products constitute nearly 82% of hospital pharmacy dispensing.

• Drug Stores & Retail Pharmacy: Drug stores and retail pharmacies account for approximately 38% of the Hemorrhoid Treatment Market, making them the second-largest distribution channel. Nearly 72% of patients with mild hemorrhoid symptoms purchase over-the-counter products before seeking physician consultation. Topical creams, ointments, medicated wipes, and suppositories represent approximately 79% of retail pharmacy sales within this therapeutic category. Pharmacist recommendations influence purchasing decisions for nearly 57% of first-time consumers.

• Online Pharmacy: Online pharmacies represent approximately 21% of the Hemorrhoid Treatment Market and continue recording strong adoption because of privacy, convenience, and home delivery services. Nearly 48% of younger adults prefer purchasing hemorrhoid medications through digital pharmacy platforms to avoid in-person consultations. Online prescription fulfillment has increased by approximately 34%, while same-day delivery services are now available to nearly 43% of urban consumers. Topical medications account for approximately 66% of online hemorrhoid product sales, followed by suppositories at 19% and oral therapies at 15%.

•   
•   
  Download Free Sample to learn more about this report

    

HEMORRHOID TREATMENT MARKET REGIONAL INSIGHTS

• North America

North America dominates the Hemorrhoid Treatment Market with approximately 39% of the global market share. The region benefits from advanced healthcare infrastructure, strong physician awareness, and high diagnosis rates. More than 10 million Americans experience hemorrhoids annually, while nearly 75% of adults develop hemorrhoids during their lifetime.

Approximately 66% of diagnosed patients receive topical pharmaceutical therapy as the first treatment option, while nearly 23% undergo minimally invasive procedures such as rubber band ligation or infrared coagulation. Hospital outpatient centers perform over 1 million anorectal procedures every year, supporting continuous demand for specialized treatment products.

• Europe

Europe accounts for approximately 28% of the Hemorrhoid Treatment Market and remains one of the most mature healthcare regions for anorectal disease management. Nearly 58% of patients receive treatment through publicly funded healthcare systems, ensuring broad access to diagnosis and medication. Approximately 64% of colorectal specialists recommend conservative pharmaceutical therapy before considering surgery.

Hospital-based outpatient procedures represent nearly 31% of hemorrhoid interventions across the region, while prescription creams and ointments account for approximately 47% of total treatment utilization. Germany, France, Italy, Spain, and the United Kingdom collectively contribute nearly 76% of European demand.

• Asia-Pacific

Asia-Pacific represents approximately 25% of the Hemorrhoid Treatment Market and is expected to remain the fastest-expanding regional healthcare market because of its large population base and improving healthcare accessibility. Nearly 60% of global population resides within Asia-Pacific, creating substantial demand for hemorrhoid diagnosis and treatment.

Approximately 44% of patients initially seek treatment through community pharmacies before consulting specialists. Pharmaceutical therapies account for nearly 74% of all hemorrhoid treatments across the region because they remain affordable and widely available. China, Japan, India, South Korea, and Australia account for approximately 81% of regional market demand.

• Middle East & Africa

The Middle East & Africa accounts for approximately 8% of the Hemorrhoid Treatment Market and continues to experience gradual expansion due to improving healthcare infrastructure and increasing public awareness. Approximately 63% of hemorrhoid patients in the region receive pharmaceutical treatment as the primary therapeutic approach, while nearly 18% undergo minimally invasive procedures.

Government investment in hospital modernization has improved access to specialized colorectal care across several countries. Urban healthcare facilities now perform approximately 36% more outpatient anorectal procedures compared with previous years. The Gulf countries contribute nearly 46% of regional demand because of higher healthcare spending and advanced hospital infrastructure.

LIST OF TOP HEMORRHOID TREATMENT COMPANIES

• Pfizer
• Ranbaxy
• Himalaya
• Astra zeneca
• Glenmark pharmaceuticals
• Glaxosmithkline plc.
• SURKON MEDICAL CO.,LTD.
• Jiangsu Kangjin Medical Instrument Co.,Ltd.
• LocaMed Limited
• Reach surgical
• Ultroid
• Sklar Surgical Instruments
• Cook
• Medline Industries, Inc.

List Of Top 2 Companies Market Share

• Pfizer – Approximately 16% market share, supported by a broad pharmaceutical portfolio, extensive global distribution network, and strong physician confidence in prescription anorectal medications.
• Glaxosmithkline plc. – Approximately 12% market share, driven by established consumer healthcare products, extensive pharmacy presence, and consistent demand for topical hemorrhoid treatment formulations.

INVESTMENT ANALYSIS AND OPPORTUNITIES

Investment activity in the Hemorrhoid Treatment Market continues to increase as pharmaceutical manufacturers and medical device companies focus on minimally invasive technologies, advanced topical formulations, and digital healthcare integration. Approximately 64% of new investments are directed toward research and development of pharmaceutical products, while 23% support minimally invasive procedural devices and 13% are allocated to manufacturing expansion and supply chain modernization. More than 58% of investment projects prioritize improving patient comfort through preservative-free creams, extended-release suppositories, and combination therapies containing anti-inflammatory and anesthetic agents.

Hospital infrastructure modernization is creating additional opportunities for manufacturers supplying disposable surgical instruments, ligation systems, and infrared coagulation devices. Nearly 72% of tertiary hospitals have expanded outpatient colorectal services, increasing demand for specialized treatment equipment. Digital health platforms are also attracting investment, with online prescription management growing by approximately 34% and telemedicine consultations for anorectal disorders increasing by 31%. Emerging economies continue presenting attractive expansion opportunities because healthcare insurance coverage has improved significantly and physician awareness programs have increased early diagnosis rates by approximately 26%.

NEW PRODUCT DEVELOPMENT

Product innovation remains a major strategic priority within the Hemorrhoid Treatment Market as manufacturers focus on improving therapeutic effectiveness, patient convenience, and treatment compliance. Approximately 61% of newly introduced products feature multi-action formulations combining anti-inflammatory, analgesic, and protective ingredients within a single treatment. Advanced topical creams containing improved absorption technology have demonstrated symptom relief within 5 days for nearly 79% of patients during routine clinical use. Suppositories with prolonged-release formulations now account for approximately 18% of new pharmaceutical launches, reducing application frequency and improving patient adherence.

Medical device innovation is progressing rapidly through the development of disposable rubber band ligation systems, precision anoscopes, and improved infrared coagulation devices. Nearly 47% of new procedural products emphasize reduced operating time and improved patient safety. Spray-based treatments with touch-free applicators continue gaining popularity, representing approximately 14% of recent product introductions because they improve hygiene and patient comfort. Herbal formulations containing botanical extracts have expanded significantly and now constitute approximately 21% of newly launched over-the-counter hemorrhoid products.

FIVE RECENT DEVELOPMENTS (2023-2025)

• February 2023: Johnson & Johnson (Ethicon) launched an upgraded hemorrhoid ligation device platform incorporating enhanced visualization and precision-guided deployment technology for minimally invasive anorectal procedures. The initiative was designed to improve procedural accuracy, reduce tissue trauma, support faster patient recovery, and strengthen the company's colorectal surgery portfolio in hospitals and ambulatory surgical centers.
• March 2023: Medtronic launched its latest disposable hemorrhoid ligation device featuring improved ergonomics, enhanced visualization, and simplified handling for physicians performing minimally invasive hemorrhoid treatment. The development focused on increasing procedural efficiency, improving clinician workflow, enhancing patient comfort, and expanding Medtronic's position in the hemorrhoid treatment device segment.
• March 2024: Cook Medical introduced a next-generation rubber band ligation system with automated band deployment, ergonomic instrument design, and real-time pressure monitoring. The innovation was developed to improve treatment precision, reduce procedural variability, optimize physician control during outpatient interventions, and strengthen Cook Medical's portfolio for hemorrhoid management.
• June 2024: Medtronic acquired Symple Surgical's hemorrhoid treatment technology portfolio, including advanced stapling and energy-based treatment technologies. The strategic acquisition expanded Medtronic's colorectal surgery capabilities, strengthened its minimally invasive treatment offerings, accelerated product innovation, and enhanced its competitive position in the global hemorrhoid treatment market.
• January 2025: Medtronic launched the HET™ Bipolar System in the European market following CE Mark approval for the treatment of Grade I and Grade II internal hemorrhoids. The system utilizes controlled bipolar radiofrequency technology to minimize tissue damage, reduce patient discomfort, shorten recovery time, and expand access to non-surgical hemorrhoid treatment across healthcare facilities.

HEMORRHOID TREATMENT MARKET REPORT COVERAGE

The Hemorrhoid Treatment Market report provides comprehensive analysis covering pharmaceutical products, minimally invasive treatment technologies, distribution channels, regional performance, competitive landscape, and emerging investment opportunities. The report evaluates major product categories including suppositories, sprays, creams & ointments, and other therapeutic solutions while analyzing their respective market shares and clinical adoption trends. It also examines key application segments consisting of hospital pharmacies, drug stores & retail pharmacies, and online pharmacies, supported by relevant statistical insights and market performance indicators.

The study further assesses regional developments across North America, Europe, Asia-Pacific, and the Middle East & Africa, highlighting healthcare infrastructure, treatment accessibility, patient demographics, and pharmaceutical utilization patterns. Competitive profiling includes major international pharmaceutical companies, medical device manufacturers, and specialized colorectal treatment providers operating within the Hemorrhoid Treatment Market. Additionally, the report evaluates innovation trends, investment priorities, product development activities, and recent manufacturer initiatives undertaken between 2023 and 2025.